ALLMedicine™ Autoimmune Pulmonary Alveolar Proteinosis Center
Research & Reviews 35 results
Lancet (London, England); Hawkins P, Chawke L et. al.
Jul 19th, 2021 - Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.|2021|Hawkins P,Chawke L,Cormican L,Wikenheiser-Brokamp KA,Fabre A,|
Journal of Medical Case Reports; Alasiri AM, Alasbali RA et. al.
Jul 10th, 2021 - Pulmonary alveolar proteinosis is a rare interstitial lung disease characterized by accumulating surfactant materials in the alveoli. The autoimmune form is by far the most common in adults, while in the pediatric age group, the vast majority of c...
Journal of Bronchology & Interventional Pulmonology; Grutters LA, Smith EC et. al.
Jun 22nd, 2021 - Autoimmune pulmonary alveolar proteinosis is an ultra-rare pulmonary disease. Whole lung lavage (WLL) is considered the gold standard therapy. We report a protocol for a new modified lavage technique (nMLT) in which controlled repetitive manual hy...
American Journal of Respiratory and Critical Care Medicine; Le Gal A, Chabrol A et. al.
Jun 16th, 2021 - Autoimmune Pulmonary Alveolar Proteinosis: Evidence of the pathogenicity of GM-CSF antibodies.|2021|Le Gal A,Chabrol A,Brun AL,Fraboulet S,Couderc LJ,|
Aging Yang Y, Xu W et. al.
Apr 7th, 2021 - Autoimmune pulmonary alveolar proteinosis (APAP) is a rare lung disease that may be associated with surfactant overaccumulation. To assess the function of long noncoding RNAs (lncRNAs) in APAP, we performed microarray analyses to identify differen...
Clinicaltrials.gov 5 results
Jan 18th, 2020 - PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure that occurs in multiple diseases that can be classified on the basis of pathogenesis into three groups: primary PAP (caused by disruption of GM-CSF signa...
Apr 12th, 2018 - The trial is a randomised, double-blind, placebo-controlled multicentre clinical trial investigating efficacy and safety of inhaled molgramostim (rhGM-CSF) in autoimmune pulmonary alveolar proteinosis (aPAP) patients. The primary objective is effi...
Oct 20th, 2017 - The purpose of the study is to evaluate the effectiveness of the sequential therapy with whole lung Lavage (WLL)/inhaling granulocyte-macrophage colony stimulating factor, compared to WLL only, for adult patients with severe autoimmune pulmonary a...
Oct 12th, 2017 - PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure that occurs in a number of diseases classified pathogenically into three groups: primary PAP (caused by disruption of GM-CSF signaling - autoimmune PAP, ...
Background: Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by accumulation of lipoproteinaceous material within alveolar spaces, leading to respiratory failure. Whole lung lavage (WLL) is the current therapeutic option, but ...